Thromb Haemost 1999; 82(06): 1610-1613
DOI: 10.1055/s-0037-1614887
Rapid Communication
Schattauer GmbH

Differences in Levels of Soluble E-selectin and VCAM-1 in Malignant versus non Malignant Mediterranean Spotted Fever

Authors

  • Françoise Dignat-George

    1   From the Laboratoire d’Hématologie, Hôpital de La Conception, Marseille, France
  • Hervé Tissot-Dupont

    2   Unité des Rickettsies, CNRS UPRES A 6020, Faculté de Médecine, Marseille, France
    3   Service des Maladies Infectieuses, Hôpital de La Conception, Marseille, France
  • Georges-Emile Grau

    1   From the Laboratoire d’Hématologie, Hôpital de La Conception, Marseille, France
    2   Unité des Rickettsies, CNRS UPRES A 6020, Faculté de Médecine, Marseille, France
  • Laurence Camoin-Jau

    1   From the Laboratoire d’Hématologie, Hôpital de La Conception, Marseille, France
  • Didier Raoult

    2   Unité des Rickettsies, CNRS UPRES A 6020, Faculté de Médecine, Marseille, France
  • José Sampol

    1   From the Laboratoire d’Hématologie, Hôpital de La Conception, Marseille, France
Further Information

Publication History

Received 21 August 1998

Accepted after resubmission 10 June 1999

Publication Date:
10 December 2017 (online)

Preview

Summary

In the present study, we investigated the plasma levels of soluble adhesion molecules E-selectin, P-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in 24 patients with Mediterranean spotted fever (MSF), 6 of whom with a malignant form. Measurements were performed on blood samples collected before treatment (T1), then twice during treatment (T2 and T3). Before treatment, MSF patients taken as a whole presented elevated levels of sICAM-1 and sVCAM-1 and normal levels of sE-selectin and sP-selectin compared to healthy controls. We found that sICAM-1 was elevated both in mild and malignant MSF. sE-selectin and sVCAM-1 were elevated only in patients with the malignant form and allowed to discriminate the two clinical subgroups. Their levels decreased after treatment with sE-selectin reaching control values at T2 whereas sVCAM-1 remained higher over the course of the malignant form. In patients with mild MSF, sP-selectin steadily increased after treatment, whereas it did not present any modification at any of the two sampling times in patients with the malignant form. Raised plasma levels of sE-selectin and sVCAM-1 reflect endothelial activation in malignant rickettsial disease and may be sufficiently early markers to influence the therapeutic decision.